On September 24, 2026, the FDA formally elevated the Automated Impella Controller (AIC) purge cassette recognition failure to a Class I recall — the agency’s most serious classification, reserved for defects with a reasonable probability of causing serious injury or death. Abiomed, the Johnson & Johnson subsidiary that manufactures Impella heart pumps, had reported 37 serious injuries and 3 deaths tied to this single defect as of August 17, 2026. This latest action caps a cascade of regulatory warnings, recalls, and mounting litigation that has made the Impella heart pump lawsuit landscape one of the most closely watched in medical device mass tort law heading into late 2026.
What Is the Impella Heart Pump and Why Is It Under Scrutiny?
The Impella is a percutaneous ventricular assist device manufactured by Abiomed and inserted through the femoral artery, then guided into the left ventricle of the heart. It is deployed during cardiogenic shock or high-risk cardiac procedures to temporarily take over the heart’s pumping function. As of 2026, Impella devices are among the most widely used mechanical circulatory support tools in U.S. hospitals — which is precisely why the volume of reported failures has alarmed both regulators and patient advocates.
When the Impella catheter perforates the wall of the left ventricle — one of the central failure modes alleged in current litigation — the consequences are catastrophic. Blood leaks into the surrounding pericardial sac, causing tamponade, and emergency open-heart surgery is typically required to repair the damage and drain the accumulating blood. Abiomed has publicly contended that heart wall tears result from operator handling rather than a device defect, and the company advises surgeons to use imaging guidance during placement and removal. Plaintiffs and the FDA’s own adverse event data tell a more complicated story. If you or a loved one suffered harm from a defective medical device, using a medical malpractice calculator can help you begin estimating the potential value of your claim.
A Timeline of Class I Recalls and FDA Safety Alerts in 2026
The regulatory record against Abiomed has grown substantially throughout 2026. What began as an isolated warning has compounded into at least five distinct Class I recalls and safety alerts spanning 2023 through September 2026, according to the FDA’s medical device recall database. Each action represents an independent failure mode, and together they paint a picture of systemic quality control and reporting deficiencies.
The sequence of events is critical for understanding the scope of the Impella heart pump lawsuit litigation:
- March 2024 — Left Ventricle Perforation Recall: A Class I recall covered 66,390 Impella left-sided blood pumps distributed between October 2021 and October 2023. Abiomed reported 30 complaints, including 26 injuries and 4 deaths, all tied to the risk that the pump catheter could perforate the left ventricle wall.
- April 3, 2026 — Purge Cassette Leak Recall: The FDA classified a purge cassette leak as a Class I recall after determining the leak risk could cause an unexpected pump stop and patient death. Abiomed reported 4 serious injuries connected to this specific issue.
- February 4, 2026 — dP Sensor Drift Warning: The FDA issued an alert after Abiomed reported sensor drift in certain Impella RP pumps, causing inaccurate blood flow and placement readings linked to more than two dozen injuries.
- May 21–22, 2026 — AIC Software Malfunction Alert: The FDA issued an early warning regarding Automated Impella Controller software malfunctions causing unexpected restarts, linked to at least 2 serious injuries and 1 death.
- September 24, 2026 — AIC Purge Cassette Recognition Failure (Class I): The FDA’s most recent and most consequential action, covering the failure of the AIC to recognize the purge cassette — resulting in 37 reported serious injuries and 3 deaths as of August 17, 2026.
- October 2025 — Cybersecurity Recall: A separate Class I recall addressed cybersecurity vulnerabilities in the Automated Impella Controller.
FDA Adverse Event Data: The Full Injury and Death Count
Beyond individual recalls, the FDA’s adverse event reporting system (MAUDE) reflects the broader toll of Impella-related failures. As of mid-2026, FDA adverse event records document at least 129 serious injuries and 49 deaths linked to Impella devices. These figures almost certainly undercount actual harm, given that the FDA also issued a Warning Letter to Abiomed citing the company’s failure to report malfunctions and deaths within the required 30-day window and its failure to meet 10-day deadlines for submitting correction plans. The Warning Letter additionally flagged Abiomed for marketing its Impella Connect remote-monitoring portal without obtaining the required premarket approval.
| Event / Recall | Date | Devices Affected | Injuries Reported | Deaths Reported | Classification |
|---|---|---|---|---|---|
| Left Ventricle Perforation Recall | March 2024 | 66,390 | 26 | 4 | Class I |
| Purge Cassette Leak | April 3, 2026 | Not disclosed | 4 | Not disclosed | Class I |
| dP Sensor Drift (Impella RP) | February 4, 2026 | Not disclosed | 24+ | Not disclosed | Safety Warning |
| AIC Software Malfunction | May 21–22, 2026 | Not disclosed | 2 | 1 | Early Alert |
| AIC Purge Cassette Recognition Failure | September 24, 2026 | Not disclosed | 37 | 3 | Class I |
| AIC Cybersecurity Vulnerabilities | October 2025 | Not disclosed | Not disclosed | Not disclosed | Class I |
| Total MAUDE Adverse Events (mid-2026) | Cumulative | — | 129+ | 49+ | Various |
Lester v. Abiomed: The Ohio Class Action Litigation Tracker
The most significant active court proceeding in the Impella heart pump lawsuit litigation is Lester v. Abiomed/Johnson & Johnson, filed in June 2025 in the Northern District of Ohio. The plaintiff, whose husband died following a left ventricle perforation during an Impella procedure, is seeking class action status on behalf of all individuals who suffered injuries or deaths related to Impella devices between January 2018 and March 2024. Families who have lost loved ones to alleged Impella device failures may benefit from consulting a wrongful death calculator to understand the range of potential compensation in cases like Lester.
On April 2, 2026, U.S. District Judge Patricia Gaughan issued a significant ruling on Abiomed’s motion to dismiss. The court dismissed the plaintiff’s fraud and Ohio Consumer Sales Practices Act (OCSPA) claims, finding they are abrogated by the Ohio Products Liability Act. However, the court allowed the core product liability and wrongful death claims to proceed — a meaningful win for plaintiffs. As of late 2026, Abiomed’s broader motion to dismiss the class action remains pending. The case’s survival past a partial motion to dismiss is an important signal for prospective plaintiffs evaluating whether to file their own Impella heart pump lawsuit. Under products liability law, manufacturers can be held strictly liable when a defective design or failure to warn causes patient harm, regardless of whether a specific operator made a handling error.
No MDL Yet: Why Early Filing Matters for Impella Victims
As of October 2026, no Multi-District Litigation (MDL) consolidation has been established for Impella heart pump claims. Individual lawsuits are active in federal and state courts nationwide, but the absence of a centralized MDL creates both risk and opportunity for injured patients. Understanding how federal multidistrict litigation procedures work can help patients and families assess what consolidation would mean for their specific case.
The strategic calculus is straightforward: when an MDL is eventually formed — and the volume of recalls, injuries, and active lawsuits makes formation increasingly likely — the first wave of plaintiffs often has greater leverage in shaping bellwether trials and early settlement discussions. Additionally, statutes of limitations for product liability and wrongful death claims vary by state and begin running from the date of injury or the date a patient reasonably discovered the connection between their harm and the device. Waiting for an MDL to form before filing can forfeit that window entirely. Patients who suffered serious injuries tied to any Impella-related recall, and family members of those who died, should document their medical records, device serial numbers, and hospital procedure dates now — well before any MDL filing deadline is imposed. If you were harmed by a defective product and want to understand your full damages, a personal injury settlement calculator can provide a starting baseline for what injured patients in similar circumstances have recovered.
Frequently Asked Questions About the Impella Heart Pump Lawsuit
Who qualifies to file an Impella heart pump lawsuit?
You may qualify to file an Impella heart pump lawsuit if you received an Impella device and suffered a serious injury such as left ventricle perforation, cardiac tamponade, emergency open-heart surgery, or other device-related complications. Family members of patients who died following an Impella procedure during which a device failure or defect may have played a role may also have standing to file a wrongful death claim. The March 2024 Class I recall specifically covered 66,390 devices distributed between October 2021 and October 2023, and the September 2026 recall covers AIC units still in active use. If your procedure involved any recalled device or model, that fact significantly strengthens your potential claim. Consult a mass tort attorney promptly, as statutes of limitations vary by state.
What injuries are linked to Impella device failures?
The FDA’s adverse event records and recall notices identify several distinct injury patterns. Left ventricle perforation — where the pump catheter punctures the heart wall — is the most severe, often requiring emergency open-heart surgery to drain blood and repair the damage. Purge system failures, including both cassette leaks and cassette recognition failures, can cause the pump to stop unexpectedly, cutting off mechanical circulatory support during a critical period. The February 2026 sensor drift warning identified inaccurate blood flow and pump placement readings in Impella RP devices, meaning clinicians may not have received accurate data needed to manage the device safely. Software malfunctions causing unexpected controller restarts have also been linked to at least one death and multiple injuries in 2026 alone. Across all reported events, the FDA’s MAUDE database reflects at least 129 serious injuries and 49 deaths as of mid-2026.
Has any court ruled in favor of Impella lawsuit plaintiffs so far?
No final judgment on the merits has been issued in any Impella case as of October 2026. However, the April 2, 2026 ruling in Lester v. Abiomed in the Northern District of Ohio represents a significant procedural victory for the plaintiff class. Judge Patricia Gaughan dismissed certain fraud and OCSPA consumer protection claims while allowing the core product liability and wrongful death claims to survive Abiomed’s motion to dismiss. This ruling confirms that plaintiffs have a viable legal path forward under Ohio products liability law, and that a federal court has found the factual allegations sufficient to proceed to discovery. The case is ongoing, and Abiomed’s full motion to dismiss remains pending as of late 2026.
Is there an MDL for Impella heart pump lawsuits?
No MDL (Multi-District Litigation) has been established for Impella heart pump lawsuits as of October 2026. Cases are currently being filed individually in federal and state courts across the country. While no MDL petition has yet been granted, the rapid accumulation of Class I recalls, the volume of FDA-documented injuries and deaths, and the active class action in Ohio create conditions under which an MDL petition could be filed and approved in the near future. Because early plaintiffs in an MDL often have greater influence over case strategy, bellwether trial selection, and settlement structure, filing before MDL formation is considered strategically advantageous by mass tort attorneys. The absence of an MDL does not diminish the validity of individual claims — it simply means each case is currently proceeding on its own track.
What compensation might be available in an Impella heart pump lawsuit?
Plaintiffs in a successful Impella heart pump lawsuit may be eligible to recover several categories of damages under product liability law. Economic damages include medical expenses (including emergency surgeries, hospitalization, rehabilitation, and future care), lost wages, and loss of earning capacity. Non-economic damages cover pain and suffering, emotional distress, and loss of enjoyment of life. In wrongful death cases, surviving family members may also recover for loss of companionship, funeral expenses, and the financial support the deceased would have provided. In cases where a manufacturer engaged in egregious conduct — such as failing to timely report known defects to the FDA, as Abiomed was cited for in its FDA Warning Letter — courts may also award punitive damages. The specific amounts vary significantly based on the severity of injury, state law caps, and the strength of the evidence connecting the device defect to the harm suffered.
This article is provided for informational purposes only and does not constitute legal advice; consult a licensed attorney in your jurisdiction regarding the specific facts of your potential Impella heart pump lawsuit claim.
Related reading: The Learned Intermediary Doctrine In Medical Malpractice: When Drug & Device Manufacturers — Not Doctors — Owe You A Warning (2026)
Related reading: COVID-Era Immunity In Medical Malpractice: What 2026 State Court Rulings Mean For Patients Who Were Harmed During The Pandemic
Related reading: Negligent Nondisclosure In Medical Malpractice: How The Duty To Disclose Affects Your Settlement (2026)
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.